|
1.
|
|
11 p, 618.2 KB |
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities : Laboratory tools for an early and differential diagnosis
/
Moreno-Castaño, Ana Belén (Hospital Clínic i Provincial de Barcelona) ;
Fernández, Sara (Hospital Clínic i Provincial de Barcelona) ;
Ventosa, Helena (Hospital Clínic i Provincial de Barcelona) ;
Palomo, Marta (Hospital Clínic i Provincial de Barcelona) ;
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ramos, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Fernández De Larrea, Carlos (Hospital Clínic i Provincial de Barcelona) ;
Urbano-Ispizua, Alvaro (Hospital Clínic i Provincial de Barcelona) ;
Penack, Olaf (Charité Universitätsmedizin Berlin, Germany) ;
Nicolás, J.M. (Hospital Clínic i Provincial de Barcelona) ;
Téllez, Adrian (Hospital Clínic i Provincial de Barcelona) ;
Escolar, Gines (Hospital Clínic i Provincial de Barcelona) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Avilés, Francesc (Hospital Clínic i Provincial de Barcelona) ;
Castro Rebollo, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Diaz-Ricart, Maribel (Hospital Clínic i Provincial de Barcelona)
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. [...]
2023 -  10.1136/jitc-2022-006365
Journal for immunotherapy of cancer, Vol. 11 Núm. 4 (april 2023)
|
|
|
2.
|
|
10 p, 2.6 MB |
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
/
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Villanueva, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Navarro, Europa Azucena (Department of Immunology. Hospital Clinic) ;
Juan, Manuel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizua, Álvaro (Department of Hematology. University of Barcelona) ;
Delgado, Julia (Centro de Investigación Biomedica en Red de Cancer) ;
Ortiz-Maldonado, Valetín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Del Bufalo, Francesca (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Locatelli, Franco (Sapienza University of Rome) ;
Quintarelli, Concetta (Department of Clinical Medicine and Surgery. University of Naples Federico II) ;
Sinibaldi, Matilde (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castro De Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urdinguio, Rocío G. (Universidad de Oviedo) ;
Fernandez, A.F. (Universidad de Oviedo) ;
Fraga, Mario F. (Universidad de Oviedo) ;
Bar, Diana (The Edmond and Lily Safra Children's Hospital) ;
Meir, Agustín (The Edmond and Lily Safra Children's Hospital) ;
Itzhaki, Orit (Ella Lemelbaum Institute for Immuno Oncology) ;
Besser, MichalJ. (Tel Aviv University) ;
Avigdor, Abraham (Sheba Medical Center) ;
Jacoby, Elad (Tel Aviv University) ;
Esteller, Manel (Universitat de Barcelona. Departament de Ciències Fisiològiques)
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. [...]
2022 - 10.1093/jnci/djab194
Journal of the National Cancer Institute, Vol. 114 Núm. 3 (january 2022) , p. 436-445
|
|
|
3.
|
|
6 p, 255.0 KB |
Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer : Supporting personalised screening
/
Román, M. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Quintana Ruiz, Maria Jesús (Institut d'Investigació Biomèdica Sant Pau) ;
Ferrer, J. (Parc Hospitalari Martí i Julià) ;
Sala, M. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Castells, X. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Universitat Autònoma de Barcelona
Our aim was to assess the cumulative risk of false-positive screening results, screen-detected cancer, and interval breast cancer in mammography screening among women with and without a previous benign breast disease and a family history of breast cancer. [...]
2017 - 10.1038/bjc.2017.107
British Journal of Cancer, Vol. 116 Núm. 11 (23 2017) , p. 1480-1485
|
|
|
4.
|
|
8 p, 509.4 KB |
GEIS-21 : A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)
/
Mora, J. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Castañeda, A. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Perez-Jaume, S. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Maradiegue, E. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Valverde, C. (Hospital Universitari Vall d'Hebron) ;
Martin-Broto, J. (Universidad de Sevilla) ;
Garcia Del Muro, X. (Hospital Universitari de Bellvitge) ;
Cruz, O. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Cruz, J. (Hospital Universitario de Canarias (La Laguna)) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Maurel, J. (Hospital Clínic i Provincial de Barcelona) ;
Vaz, M.A. (Hospital Ramón y Cajal) ;
De Alava, E. (Universidad de Sevilla) ;
De Torres, C. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study for patients 1/240 years with newly diagnosed ES. [...]
2017 - 10.1038/bjc.2017.252
British Journal of Cancer, Vol. 117 Núm. 6 (may 2017) , p. 767-774
|
|
|
5.
|
|
8 p, 535.7 KB |
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
/
Joensuu, Heikki (Helsinki University Hospital) ;
Blay, Jean-Yves (University Claude Bernard Lyon I) ;
Comandone, Alessandro (Gradenigo Hospital) ;
Martin-Broto, Javier (Hosp o Virgen del Rocío (Sevilla, Andalusia)) ;
Fumagalli, Elena (Fondazione IRCCS Istituto Nazionale Dei Tumori) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Del Muro, Xavier Garcia (Hospital Universitari de Bellvitge) ;
Adenis, Antoine (Centre Oscar Lambret) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Bouche, Olivier (University Hospital Robert Debre) ;
Italiano, Antoine (Comprehensive Cancer Centre. 2Institut Bergonie) ;
Bauer, Sebastian (University of Duisburg- Essen) ;
Barone, Carlo (University Hospital A. Gemelli) ;
Weiss, Claudia (Novartis Pharma GmbH) ;
Crippa, Stefania (Novartis Farma) ;
Camozzi, Maura (Novartis Farma) ;
Castellana, Ramon (Novartis Farmaceutica SA) ;
Le Cesne, Axel (Gustave Roussy) ;
Universitat Autònoma de Barcelona
This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. [...]
2017 - 10.1038/bjc.2017.290
British Journal of Cancer, Vol. 117 Núm. 9 (2017) , p. 1278-1285
|
|
|
6.
|
|
6 p, 291.5 KB |
Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
/
Martín, A.J.M. (Hospital General Universitario Gregorio Marañón) ;
Ortega, I. (Gendiag) ;
Font, Carme (Hospital Clínic i Provincial de Barcelona) ;
Pachón, V. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Castellón, V. (Complejo Hospitalario de Torrecárdenas) ;
Martínez-Marín, V. (Hospital Universitario La Paz (Madrid)) ;
Salgado, M. (Complejo Hospitalario Universitario de Ourense) ;
Martínez, E. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Calzas, J. (Hospital Universitario de Fuenlabrada ( Madrid)) ;
Rupérez, A. (Hospital Universitario Fundación Jiménez Díaz) ;
Souto, Juan Carlos (Institut d'Investigació Biomèdica Sant Pau) ;
Martín, M. (Hospital General Universitario Gregorio Marañón) ;
Salas, E. (Gendiag) ;
Soria Fernández, José Manuel (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. Outpatients with cancer should be periodically assessed for VTE risk, for which the Khorana score is commonly recommended. [...]
2018 - 10.1038/s41416-018-0027-8
British Journal of Cancer, Vol. 118 Núm. 8 (january 2018) , p. 1056-1061
|
|
|
7.
|
|
11 p, 529.4 KB |
Nivolumab and sunitinib combination in advanced soft tissue sarcomas : A multicenter, single-arm, phase Ib/II trial
/
Martin-Broto, J. (Universidad de Sevilla) ;
Hindi, Nadia (Universidad de Sevilla) ;
Grignani, G. (Candiolo Cancer Institute) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Redondo, A. (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Stacchiotti, S. (Istituto Nazionale Tumori) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
D'Ambrosio, L. (Candiolo Cancer Institute) ;
Gutierrez, A. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Perez-Vega, H. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Encinas-Tobajas, V. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
De Álava, Enrique (Universidad de Sevilla) ;
Collini, Paola (Istituto Nazionale Tumori) ;
Peña-Chilet, M. (Hospital Virgen Del Rocio) ;
Dopazo, J. (Hospital Virgen Del Rocío) ;
Carrasco-Garcia, I. (Universidad de Sevilla) ;
Lopez-Alvarez, M. (Universidad de Sevilla) ;
Moura, D.S. (Universidad de Sevilla) ;
Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Universitat Autònoma de Barcelona
Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. [...]
2020 - 10.1136/jitc-2020-001561
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (17 2020) , p. e001561
|
|
|
8.
|
|
6 p, 380.2 KB |
Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer : final results of a randomised phase 2 clinical trial
/
Gridelli, C. (S.G. Moscati Hospital) ;
Ciuleanu, Tudor Eliade (Institutui. Oncologic I. Chircuta) ;
Domine, M. (Fundacion Jimenez Diaz) ;
Szczesna, A. (Mazowieckie Centrum) ;
Bover, I. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Cobo, M. (Instituto de Investigaciones Biomédicas (IBIMA)) ;
Kentepozidis, N. (251 General Airforce Hospital) ;
Zarogoulidis, K. (Papanikolaou General Hospital) ;
Kalofonos, C. (University Hospital of Patras) ;
Kazarnowisz, A. (Oddzial Onkologiiz Pododdziatem) ;
Korozan, M. (Hospicjum Dutkiewicza SAC) ;
de las Peñas, R (Hospital Provincial de Castellon) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Chella, A. (A.O.U. di Pisa Hospital) ;
Griesinger, F. (Pius Hospital) ;
Bournakis, E. (University Hospital "Aretaieion") ;
Sadjadian, P. (Johannes Wesling Klinikum) ;
Kotsakis, A. (University General Hospital of Larissa) ;
Chinet, T. (Hopital Ambroise Paré) ;
Syrigos, K.N. (General Hospital of Thoracic Diseases "Sotiria") ;
Correale, P. (University Hospital of Siena) ;
Gallou, C. (Vaxon-Biotech) ;
Jamet, J.M. (Vaxon-Biotech) ;
Vetsika, E.K. (University General Hospital of Heraklion) ;
Kosmatopoulos, K. (Vaxon-Biotech) ;
Georgoulias, V. (University General Hospital of Heraklion) ;
Universitat Autònoma de Barcelona
The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC). [...]
2020 - 10.1038/s41416-020-0785-y
British Journal of Cancer, Vol. 122 Núm. 10 (december 2020) , p. 1461-1466
|
|
|
9.
|
|
|
10.
|
|
13 p, 31.6 MB |
Extracellular vesicles secreted by triple-negative breast cancer stem cells trigger premetastatic niche remodeling and metastatic growth in the lungs
/
González-Callejo, Patricia (Instituto de Salud Carlos III) ;
Gener, Petra (Instituto de Salud Carlos III) ;
Díaz Riascos, Zamira Vanessa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Conti, Sefora (Institut de Bioenginyeria de Catalunya) ;
Cámara-Sánchez, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Riera Brillas, Roger (Department of Biomedical Engineering. Eindhoven University of Technology) ;
Mancilla, Sandra (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Gabilondo, Miguel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Peg, Vicente (Centro de Investigación Biomédica en Red de Cáncer) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rosell Novel, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Labernadie, Anna (Institut de Bioenginyeria de Catalunya) ;
Trepat, Xavier (Institució Catalana de Recerca i Estudis Avançats) ;
Albertazzi, Lorenzo (Department of Biomedical Engineering. Eindhoven University of Technology) ;
Schwartz, S. (Instituto de Salud Carlos III) ;
Seras-Franzoso, Joaquin (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Abasolo, Ibane (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Tumor secreted extracellular vesicles (EVs) are potent intercellular signaling platforms. They are responsible for the accommodation of the premetastatic niche (PMN) to support cancer cell engraftment and metastatic growth. [...]
2023 - 10.1002/ijc.34447
International Journal of Cancer, Vol. 152 Núm. 10 (15 2023) , p. 2153-2165
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
